Prima BioMed Ltd. announced that the amended CAN-004 protocol was approved by the Belgian Federal Agency for Medicines and Health Products. This is the first regulatory agency to approve the amended CVac(TM) clinical trial design. CAN-004 is a multicentre, randomized, phase 2 trial of CVac for the maintenance treatment of epithelial ovarian cancer in remission.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 AUD | -1.67% |
|
-1.67% | -14.49% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.49% | 287M | |
+21.85% | 47.96B | |
+0.85% | 42.45B | |
+43.96% | 41.47B | |
+26.41% | 31.6B | |
+20.88% | 28.63B | |
-4.47% | 28.03B | |
+52.06% | 14.56B | |
+45.41% | 14.14B | |
+2.70% | 12.58B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Prima BioMed Ltd.'s Can-004 Clinical Trial Amendment Approved in Belgium